Modernization and Expansion of the Citigroup Biomedical Imaging Center at Weill Cornell Medical College

摘要 拟建项目涉及重大现代化建设和快速发展的重点建设 纽约曼哈顿威尔·康奈尔医学院花旗生物医学成像中心(CBIC) 城市。CBIC是一个全面的影像研究资源，致力于开发新的 生物医学成像技术支持广泛从事诊断和治疗的研究人员 人类疾病的治疗。自2001年成立以来，中银保监会已为100多名委托人提供常规服务 任何一年来自10多个机构的调查人员(2022年来自14个机构的148个小组，我们的 有史以来最大的使用量)。这项由CBIC支持的研究具有国内和国际影响，原因是 许多研究人员在各自的学科中处于领先地位，领导着大型多机构研究 项目，发明新的成像技术，并在世界各地招募人类受试者。项目的范围 在CBIC影像资源的支持下，非常广泛，包括神经外科、精神病学、 神经退行性疾病、肿瘤学、骨科、遗传医学和结构生物学。年度总数 得到支持的NIH赠款的成本通常超过5000万美元。2022年，NIH资助的项目达到创纪录的172个 都得到了中银国际的支持，总成本超过1.18亿美元。该中心提供十大成像和 人体和临床前研究的光谱平台，包括磁共振成像(MRI) 以及光谱学、正电子发射断层扫描(PET)、计算机断层扫描(CT)、单光子发射 计算机断层扫描、超声波和光学成像。此外，完整的回旋加速器和放射化学 设施齐全。自中心成立以来，我们现在已经超过了20年的大关，我们 迫切需要进行重大现代化和基础设施建设，以便继续提供 一个安全、最先进的环境，用于人体和动物模型的成像研究 对于我们迅速增加的调查员队伍来说，这是一种疾病。为了满足我们现在和未来的需要，我们 提出以下五个项目组成部分：1)建造一个新的正电子发射装置 断层扫描/计算机断层扫描(PET/CT)套件，首次促进全身PET，2) 一套新型现代高场核磁共振波谱系统的构建 高场核磁共振光谱仪，3)更新我们的放射性药物生产套件，使我们能够 生产我们的高需求碳-11标记放射性示踪剂所需的放射化学与 用其他放射性同位素生产的示踪剂，4)安装油罐歧管和供应管路，以使一般 麻醉能力，使我们能够接受比目前可能接受的更广泛的研究对象，5) 为两台关键扫描仪(一台核磁共振和一台正电子发射计算机断层扫描仪)增加电气基础设施，以确保瞬时电力 最大限度地减少了中断，从而显著提高了正在进行和预期的映像的安全性- 指导性治疗干预。

ABSTRACT The proposed project involves major modernization and focused construction at the rapidly growing Citigroup Biomedical Imaging Center (CBIC) of Weill Cornell Medical College in Manhattan, New York City. The CBIC is a comprehensive imaging research resource dedicated to the development of new biomedical imaging techniques in support of a wide range of investigators engaged in the diagnosis and treatment of human disease. Since its inception in 2001, the CBIC has routinely served over 100 Principal Investigators from more than 10 institutions in any given year (148 groups from 14 institutions in 2022, our largest usage ever). The research supported by the CBIC has both a national and international impact due to the many investigators who are leaders in their respective disciplines, lead large multi-institutional research projects, invent new imaging techniques, and recruit human subjects worldwide. The range of projects supported with CBIC imaging resources is extremely broad, and includes studies in neurosurgery, psychiatry, neurodegenerative disease, oncology, orthopedics, genetic medicine, and structural biology. The annual total costs of NIH grants that are supported typically exceeds $50 million. In 2022, a record 172 NIH funded projects were supported by CBIC with total costs of over $118 million. The Center offers ten major imaging and spectroscopy platforms for both human and pre-clinical studies, including magnetic resonance imaging (MRI) and spectroscopy, positron emission tomography (PET), computed tomography (CT), single photon emission computed tomography, ultrasound, and optical imaging. In addition, complete cyclotron and radiochemistry facilities are available. We have now surpassed the 20-year mark since the Center was established, and we have an urgent need for major modernization and construction of infrastructure in order to continue to provide a safe, state-of-the-art environment for imaging studies involving both human subjects and animal models of disease for our rapidly increasing pool of investigators. In order to meet our present and future needs, we propose the following five project components: 1) Construction of a new positron emission tomography/computed tomography (PET/CT) suite, facilitating whole-body PET for the first time, 2) construction of a new modern high field nuclear magnetic resonance (NMR) spectroscopy suite for our three high field NMR spectrometers, 3) renovation of our radiopharmaceutical production suite, allowing us to separate radiochemistry needed for production of our high demand carbon-11 labeled radiotracers from that of tracers produced with other radioisotopes, 4) installation of tank manifolds and supply lines to enable general anesthesia capability, allowing us to accept a wider range of research subjects than is currently possible, 5) addition of electrical infrastructure to two key scanners (one MRI and one PET) to ensure that transient power interruptions are minimized, thereby significantly increasing the safety of ongoing and anticipated image- guided therapeutic interventions.